


## Rough guide for S/C Insulin Stat dose -

- CBS: 180-250 S/C Insulin 4-6 units
- CBS: 250-350 S/C Insulin 6-10 units
- CBS: 350-450 S/C Insulin 8-15 units
- CBS: 450-HI S/C Insulin 15-20 units

## Annex 1

## Hypoglycaemia in patients with DM




Symptoms of hypoglycemia include, but are not limited to, shakiness, irritability, confusion, tachycardia, sweating, and hunger.

Because many people with diabetes experience impaired hypoglycemia awareness, a measured glucose level <70 mg/dL (<3.9 mmol/L) is considered clinically important, regardless of symptoms.

## Algorithm for the Management of Hypoglycaemia in Adults with Diabetes in Hospital

Hypoglycaemia is a serious condition and should be treated as an emergency regardless of level of conciousness. Hypoglycaemia is defined as blood sugar glucose of <4.0mmol/L (if not <4.0mmol/L but symptomatic give a small carbohydrate snack for symptom relief) See full guideline "The Hospital Management of Hypoglycaemia in Adults with Diabetes Mellitus" at www.diabetes.org.uk/joint-british-diabetes-society



## Level 1 and 2 hypoglycaemia Management (mild-mod)-

Rapid acting Carbohydrate 15-20 g in Sri Lankan setting-

• 15-20 g of pure glucose preferred

## Alternatives-

- 150-200ml pure fruit juice (e.g. orange juice), do not use if following a low potassium diet (e.g. to treat chronic kidney disease) in view of its potassium content.
- 3-4 heaped teaspoons of sugar dissolved in water.
- In moderate hypoglycaemia, glucose dissolved in water can be applied to buccal mucosa as an alternative to dextrose gel.
- Once blood glucose is above 4.0mmol/L and the person has recovered, give a long acting carbohydrate snack (20g) of their choice where possible, taking into consideration any specific dietary requirements.
- People given glucagon require a larger portion of long-acting carbohydrate (40g) to replenish
  glycogen stores (double the suggested amounts below) although nausea associated with
  glucagon injections may be an issue.
  - Examples include: a. Two biscuits b. One slice of bread/toast c. 200-300ml glass of milk (not soya or other forms of 'alternative milk, e.g. almond or coconut) d. Normal meal if due (must contain carbohydrate).

## Level 3 hypoglycaemia-

- Immediate treatment with 25g of 25-50% glucose solution administered IV.
- No IV access-

If no IV access is available then give 1mg Glucagon IM. Glucagon is only licensed for insulin induced hypoglycaemia and may be less effective in people prescribed sulfonylurea therapy (may take up to 15 minutes to take effect).

Glucagon mobilises glycogen from the liver and will be less effective in those who are chronically malnourished (including those who have had a prolonged period of starvation), abuse alcohol or have chronic liver disease.

In this situation IV glucose is the preferred option. If no IV access is available initially, continue trying to achieve IV access as IM glucagon is less likely to be successful if required for a second time.


## References

- 1. Joint British Diabetes Societies guideline on The Hospital Management of Hypoglycaemia in Adults with Diabetes Mellitus, January 2023 Revision
- 2. American Diabetes Association **Glycemic Goals and Hypoglycemia**: **Standards of Care in Diabetes—2024**
- 3. Upto date

## Hypoglycaemia in patients without DM

Management of hypoglycaemia according to severity similar to patients with DM and hypoglycaemia.


## Evaluation of hypoglycemic symptoms in adults without diabetes mellitus



- \* If laboratory glucose measurement is pursued, insulin, C-peptide, and proinsulin levels should be obtained concurrently at the time of hypoglycemic symptoms. A detailed approach to home blood glucose monitoring with fingersticks and a glucose meter is described in other UpToDate content. Continuous glucose monitoring should **not** be used in the evaluation of hypoglycemic symptoms in individuals without diabetes.
- ¶ The duration of continued monitoring depends on factors including frequency of hypoglycemic symptoms and clinical suspicion for an underlying hypoglycemic disorder.

Δ Supervised testing can entail a supervised fast or mixed meal test, or evaluation may be performed during a spontaneous episode of hypoglycemia. Selection of a supervised test when hypoglycemia is not fortuitously observed depends on the timing of symptoms in relation to meals.

# Evaluation of hypoglycemia in asymptomatic adults without diabetes mellitus



- \* Artifactual hypoglycemia can occur if an antiglycolytic agent (eg, fluoride) is not present in the blood collection tube and sample processing is delayed. Artifactual hypoglycemia also may be seen in individuals with leukocytosis, erythrocytosis, or hemolysis.
- $\P$  A low glucose value is less likely to reflect normal physiology in individuals aged  $\geq$ 40 years and usually warrants further evaluation.

Δ Individuals who report the loss of a symptomatic response to hypoglycemia over time should undergo additional evaluation as this history could reflect the evolution of impaired awareness of hypoglycemia that can occur with recurrent episodes of hypoglycemia.

♦ Supervised testing can entail a supervised fast or mixed meal test, or evaluation may be performed during a spontaneous episode of hypoglycemia. Selection of a supervised test when hypoglycemia is not fortuitously observed depends on the timing of symptoms in relation to meals.

§ In young (aged <40 years), healthy individuals, glucose values  $\geq$ 40 to 64 mg/dL (2.2 to 3.6 mmol/L) can reflect normal physiology in the fasting state.

## Causes of hypoglycemia in adults

l or medicated individu	ıal
1. Drugs	
Insulin or insulin secretage	ogue
Alcohol	
Others (refer to UpToDate	table on drugs that cause hypoglycemia)
2. Critical illnesses	
Hepatic, renal, or cardiac f	ailure
Sepsis (including malaria)	
Inanition	
3. Hormone deficiency	
Cortisol	
Glucagon and epinephrine	(in insulin-deficient diabetes mellitus)
4. Nonislet cell tumor	
eemingly well individu	al
5. Endogenous hyperins	ulinism
Insulinoma	
Functional beta cell disord	ers (nesidioblastosis)
Noninsulinoma pancre	atogenous hypoglycemia
Post-gastric bypass hyp	ooglycemia
Insulin autoimmune hypo	glycemia
Antibody to insulin	
Antibody to insulin rece	eptor
Insulin secretagogue	
Other	

Reproduced with permission from: Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94:709. Copyright © 2009 The Endocrine Society.

# Drugs other than antihyperglycemic agents and alcohol reported to cause hypoglycemia

Moderate q	uality of evidence
Cibenzoline	
Gatifloxacin	
Pentamidine	
Quinine	
Indomethacin	
Glucagon (dur	ing endoscopy)
Low quality	of evidence
Chloroquineo	aline sulfonamide
Artesunate/ar	remisin/artemether
IGF-1	
Lithium	
Propoxyphene	/dextropropoxyphene
Very low qu	ality of evidence
Drugs with	>25 cases of hypoglycemia identified
Angiotensii	n-converting enzyme inhibitors
Angiotensii	receptor antagonists
Beta-adren	ergic receptor antagonists
Levofloxaci	n
Mifepriston	e
Disopyrami	de
Trimethopr	im-sulfamethoxazole
Heparin	
6-mercapto	purine

IGF-1: insulin-like growth factor-1.

## Reference

Upto date section on hypoglycaemia in adults without Diabetes.

## Annex 2 – DKA Management



## The Management of Diabetic Ketoacidosis in Adults



Where individuals aged 16-18 are managed by paediatric teams, the paediatric guidelines should be followed: BSPED IBSPED DKA Guidelines

## Diagnostic criteria: all three of the following must be present

- capillary blood glucose above 11 mmol/L
- capillary ketones above 3 mmol/L or urine ketones ++ or more
- venous pH less than 7.3 and/or bicarbonate less than 15 mmol/L

# BOX 1: Immediate management: time 0 to 60 minutes (T=0 at time intravenous fluids are commenced) If intravenous access cannot be obtained request critical care support immediately Action 4: Further investigations

Action 1: Commence 0.9% sodium chloride solution (use a large bore cannula) via an infusion pump International Control of the Control

# Venous BG U&E and FBC Blood cultures ECG CXR MSU

# HDUlevel 2 facility and/or insertion of central line may be required in following circumstances (request urgent senior review) - Young people aged 18-25 years - Elderly - Pregnant - Heart or kidney failure - Heart or kidney failure - Cher serious co-morhidities - Severe DKA by following criteria - Blood ketones above 6 mmol/L - Venous bicarbonate below 5 mmol/L - Anion gap above16 [Anion Gap = (Na\* + K\*) – (Ci\* + K\*)

- Venous pH below 7.0
  Hypokalaemia on admission (below 3.5 mmol/L)
  GCS less than 12
  Oxygen saturation below 92% on air (Arterial blood gases required)
  Systolic BP below 90 mmHg
  Pulse over 100 or below 60 bpm
  Anion gap above16 [Anion Gap = (Na\* + K\*) (Cl\* + HCO<sub>3</sub>\*)]

litre of fluid

Systolic BP on admission 90 mmHg and over

- Give 11.0 9% sodium chloride over the first 60 minutes

Potassium replacement

Potassium replacement mmol/L of infusion solution

> 5.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

- 8.5

BOX 3: 60 minutes to 6 hours

lims of treatment:
Rate of fall of ketones of at least 0.5 mmol/Lhr OR bicarbonate rise 3
mmol/Lhrand blood glucose fall 3 mmol/Lhr
Maintain serum potassium in normal range

- Maintain serum potassium in normal range
  Avoid hypotyceima
  Houly blood kelones if meter available
  Venous blood gas for plt, bicarbonale and potassium at 80 minutes, 2
  hours and 2 hourly thereafter
  if potassium is outside normal range, ne-assess potassium replacement
  indicate and your disconneal and professional avoid in the service of the s

- More cautious fluid representations (Consider HDU announced clerky, prepared, head or renal failure. (Consider HDU announced clerky, prepared, head or renal renal

- Nasogastic tube with airway protection if patient obtunded or persis vomiting Measure arterial blood gases and repeat chest radiograph if oxygen saturation less than 92% Thromboprophylaxis with low molecular weight heparin Consider ECG monitoring if potassium abnormal or concerns about cardiac status.

## BOX 4: 6 to 12 hours

Kins:
Ensure clinical and biochemical parameters in improving
Continue IV fluid replacement
Avoid hypotylecemia
Avoid hypotylecemia
overload, cerebral oedema
Treat precipitaling factors as necessary
Action 1. Re-assess patient, monitor vital signs
I patient of the improving by criteria is Box 3, seek

## Reassess cardiovascular status at 12 hours; further fluidmay be required

## Check for fluid overload

- Assess for complications of treatment e.g. fluid
  Assess for complications of treatment e.g. fluid
  Action 1: Reassess patient, monitor vital signs
  Action 1: Reassess patient, monitor vital signs
  (If patient not impriving by criteria in Box 3, seeks senior advice.

  1: patient not impriving by criteria in Box 3, seeks senior advice.

  2: 0.9% sould moticrise 1 tulk hit Cover 4 hours

  0: 0.9% sould moticrise 1 tulk hit Cover 4 hours

  0: 0.9% sould moticrise 1 tulk hit Cover 4 hours

  0: 0.9% sould moticrise 1 tulk hit Cover 6 hours

  1: Formatier reducing the rate of intravenous insulin

  1: WKA not resolved review insulin infusion (see
  BOX 3Action 3)

  1: HDKA nesolved go to BOX 6

- EU.S.: 12 to 24 FOURS

  Expectation, 19 4 hours the Notomerian and addois should have resolved. Request senior review is not improving an addoise and addoise and some the decision of the control of the

- Action 1—Re-seps patient, monitor vital signs
  Action 2—Review blochemical and metabolic parameters
  Action 2—Review blochemical and metabolic parameters
  and gloose

   Resolution is defined as lectores 0.6 remoil, venue, pt-P3

   In our tender deven full disc A Action 1 and result inclusion Box 3

  Action 3

  INCA resolved go to Box 6

Expectation: Patient should be eating and drinking and back on normal insulin If DKA not resolved identify and treat the reasons for failure to respond This situation is unusual and requires senior and specialist input

This alturation is unusual and requires senior and specialist input Transefro subcutaneous insulin Convert to subcutaneous regime when bochemically stable (capillary ketones best han 0.6 mmolt. AND pH over 7.3 and the patient is ready and able to eat. Do not discontinue intravenous insulin infusion until 30 minutue sire subcutaneous short acting insulin has been given Conversion to subcutaneous hand to the subcutaneous short acting insulin has been given Conversion to subcutaneous beam in road realistic use local guidations. If the patient is newly diagnosed it is essential they are seen by a member of the specialist team prior to discharge.















Represented: Association of British Clinical Diabetologists; British Society for Endocrinology and Diabetes and Association of Children's Diabetes Clinicians; Diabetes Inpatient Specialist Nurse (DISN) Group; Diabetes UK; Diabetes Network Northern Ireland; Society of Acute Medicine; Welsh Endocrine and Diabetes Society, Scottish Diabetes Group.


## Annex 3 – HHS Management

### IBDS-IP Joint British tor Inpatient care Hyperosmolar Hyperglycaemic State (HHS) care pathway in adults Clinical features (all the below) Aims of therapy Criteria for resolution of HHS: Holistic assessment of the following: 1) Marked hypovolaemia 1) Improvement in clinical status and replacement of all estimated fluid losses by 24 hours A mixed picture of 1) Clinical and cognitive status is back to the pre-morbid state HHS and DKA occurs 2) Osmolality ≥320 mOsm/kg 2) Gradual decline in osmolality: drop of 3-8 mOsm/kg/hr relatively frequently 3) Marked hyperglycaemia (≥30 mmol/L) 3) Blood glucose: aim to keep to 10-15 mmol/L in the first 24 hours 2) Osmolality <300 mOsm/kg 4) Without significant ketonaemia (≤3.0 mmol/L) 4) Avoid hypoglycaemia and hypokalaemia 3) Hypovolaemia has been corrected (urine output ≥0.5 ml/kg/hr) Without significant acidosis (pH ≥7.3) and bicarbonate ≥15 mmol/L 5) Prevent harm: VTE, osmotic demyelination, fluid overload, foot ulceration 4) Blood glucose <15 mmol/L Time 0-60 minutes 60 minutes - 6 hours 6-12 hours 12-24 hours 24-72 hours Clinical assessment and monitoring History/Examination, NEWS, cardiac monitoring, urine output Establish adequate intravenous lines (preferably 2 large bore IV cannulas) Discuss with outreach/ICU team early if there are markers of high severity (see Table 1 overleaf) Clinical status / NEWS Check for continuing improvement Expect steady recovery, patient eating and drinking, and blochemistry as it was prior to HHS Assess for precipitating cause(s): sepsis, diabetic foot infection, treatment omissions, vulnerable adult, vascular event (myocardial infarction, stroke) Ongoing management of the precipitating Precipitating cause(s) cause(s) Ongoing management of the precipitating cause(s) Osmolality (VBG/blood) Check every hour for 6 hours Measure/calculate (2xNa\*) + Glucose + Urea heck every 4 hours (if no clinical imp Until the urea is available, calculate using (2 x Na\*+ glucose). Recalculate osmolality once urea is Replacement of all estimated fluid losses by 24 hours then check every 2 hours) available, and then use (2 x Na" + glucose + urea) Aim for gradual decline of 3-8 mOsm/kg/hr Individual BG target 6-10 mmol/L ow to interpret osmolality results Check Figure 1 overleaf Check Figure 1 overleaf Check Figure 1 overleaf Check Figure 1 overleaf Check every hour Fall in BG should be up to 5.0 mmol/L per hour (check Figure 2 overleaf for details) Check every hour (check Figure 2 overleaf for details) Check every hour (check Figure 2 overleaf Blood glucose (BG) (Aim for 10-15 mmol/L in the first 24 hours) for details) Interventions travenous fluids (0.9% saline) Aim for up to 6 litres positive balance 1 litre over 1 hour Reassess fluid balance to plan fluids Aim for 2-3 litres positive balance by 6 hours Can be stopped if patient is eating and drinking (In IV line 1) (caution in HF/CKD/BW <50 kg) by 12 hours replacement for the next 12 hours (caution in HF/CKD/BW <50 kg) Use DKA guidelines if ketonaemia (>3.0 mmol/L) or ketonuria (≥2+) sulin infusion VRIII if not eating and drinking Only commence if positive fluid balance and BG plateaued on repeated measurements (>2 occasions) Rate may need adjustment to 1 unit/hr to achieve BG target 10-15 mmol/L (FRIII 0.05 units/kg/hr using Actrapid\*) (In IV line 2) Start FRIII if ketonaemia (>1.0 - s3.0 mmol/L) or ketonuria (<2+) Otherwise convert to subcutaneous insulin Glucose infusion: 5% or 10% @ 125ml/hr Not required at this stage Only initiate if BG <14 mmol/L Continue infusion at 125 ml/hr Can be stopped if patient is eating and drinking Check Table 2 overleaf for potassium replacement guidelines Check Table 2 overleaf for potassium replacement guidelines Check Table 2 overleaf for potassium Check U&Es daily replacement guidelines Assessments and prevention VTE prophylaxis (low molecular weight heparin) Assess for complications e.g. fluid overload, cerebral oedema, osmotic demyelination (deteriorating conscious level) VTE prophylaxis until discharge Daily feet checks Prevent harm Glucose 5% or 10% at 125 ml/hr if BG <14 mmol/L Target BG 6-10 mmol/L Prevent foot ulceration Daily foot checks Daily foot checks Review by inpatient diabetes team before discharge Escalate management if there is clinical deterioration Abbreviations: 8G=blood glucose; BW=body weight; CKD=chronic kidney disease; FRIII=fixed rate intravenous insulin infusion; HF=heart failure; hr=hour; ICU=intensive care unit; IV=intravenous; kg=kilograms; NEWS=national early warning score; U&Es=urea and electrolytes; VBG=venous blood gas analysis; VRIII=variable rate intravenous insulin infusion; VTE=venous thromboembolism

@JBDSIP 2022

## Hyperosmolar Hyperglycaemic State (HHS) care pathway in adults





management according to the individual's need

# Table 1: Escalate to ICU/outreach if any of the following is present:

- Osmolality >350 mOsm/kg
- Sodium >160 mmol/L
- Venous/arterial pH <7.1</li>
- Hypokalaemia (<3.5 mmol/L) or hyperkalaemia (>6 mmol/L) on admission
- Glasgow Coma Scale (GCS) <12 or abnormal AVPU (Alert, Voice, Pain, Unresponsive)
- Oxygen saturation <92% on air (assuming normal baseline respiratory function)
- Systolic blood pressure <90 mmHg</li>
- Pulse >100 or <60 beats per minute
- Urine output <0.5 ml/kg/hour
- Serum creatinine >200 µmol/L and/or Acute kidney injury
- Hypothermia
- Macrovascular event such as myocardial infarction or stroke
  - Other serious co-morbidity

## Table 2: Potassium replacement guidelines

Potassium level in first 24 hours (mmol/L)	Potassium replacement in infusion solution
≥6.0	Senior review ICU/outreach
5.5-5.9	Nil
3.5-5.5	40 mmol/L
<3.5	Senior review ICU/Outreach. Additional potassium is required

## Annex 4

## DIABETÉS TREATMENT ALGORITHM CHART

CBS VALUE <60mg/dl

ALG	ALGORITHM 1		RITHM 2	ALGORITHM 3		ALGORITHM 4	
CBS VAI	Contract of the last of the la	The same of the sa	INSULIN (u/hr)	CBS VALUE (mg/dl)	INSULIN (u/hr)	CBS VALUE (mg/dl)	INSULIN (u/hr)
<70	OF	F <70	OFF	<70	OFF	<70	OFF
70-109	0.2	70-109	0.5	70-109	1	70-109	1.5
110-119	0.5	110-119	1	110-119	2	110-119	3
120-149	1	120-149	1.5	120-149	3	120-149	.5
150-179	1.5	150-179	2	150-179	4	150-179	7.5
180-209	2	180-209	3	180-209	5	180-209	9
210-239	2 -	210-239	4	210-239	6	210-239	12
240-269	3	240-269	5 ~	240-269	8	240-269	16
270-299	3	270-299	6	270-299	10	270-299	20
300-329	4	300-329	7	300-329	12	300-329	24
330-359	4	330-359	8	330-359	14	330-359	28
>360	6	>360	12	>360	16	>360	32

## Annex 5 - Correctional Dose

3 components of insulin required for a patient in hospital.

1.Basal Insulin and 2. Bolus insulin

Pre-admission dose or 0.5u/kg - > 50% as basal and 50% as bolus insulin. Can be given as Mixtard Insulin or basal insulin (eg NPH/ glargine) and bolus insulin (eg soluble insulin/ rapid acting analogue) with meals .

+

3.Correctional dose

Provides real time adjustment of insulin dosing based on insulin sensitivity.

In a normal patient 1 unit of pre-meal soluble insulin will reduce the next pre-meal CBS by 10mg/dL.

Correctional dose needs to be calculated to relate this to patients with impaired insulin sensitivity.

## **Correctional dose calculation**

Correctional factor (CF)= 1700/TDD (Total Daily Insulin)

Or

3000/Body weight (kg)

## **Correction Bolus Formula**

Current BG - Ideal BG

Glucose correction factor

## **Example for correctional dose calculation**

Blood sugar pre-lunch: 200mg/dL

Pre- meal goal: 140mg/dL

200-140=60mg/dL

Total Daily Insulin = 50 U CF= 1700/50=34

Extra dose of Insulin needed to cover 60mg/dL= 60/ 34=1.8 Give extra 2 units of Insulin for pre-lunch dose